BDRX
Biodexa Pharmaceuticals Plc
Biotechnology
Market Cap$1M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BDRX vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-59.3%
BDRX vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BDRX | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-12M | $-168M |
| Total Debt | $61K | $22M |
| Cash & Equiv. | $9M | $194M |
BDRX vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BDRX
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Biodexa Pharmaceuti… (BDRX) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 40.7 | -59.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BDRX vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BDRX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BDRX
Biodexa Pharmaceuticals Plc
The Income Pick
BDRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.25
- Rev growth -100.0%, EPS growth 100.0%
- Lower volatility, beta 1.25, Low D/E 0.5%, current ratio 2.03x
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.0% 10Y total return vs BDRX's -100.0%
- 0.3% margin vs BDRX's 0.1%
- +110.4% vs BDRX's -93.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BDRX | -100.0% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs BDRX's 0.1% |
| Stability / Safety | BDRX | Beta 1.25 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs BDRX's -93.0% |
| Efficiency (ROA) | BDRX | -78.4% ROA vs DBVT's -89.0% |
BDRX vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBDRXLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
BDRXBiodexa Pharmaceutica…
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BDRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BDRX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BDRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BDRX and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$18M | -$112M |
| Net IncomeAfter-tax profit | -$12M | -$168M |
| Free Cash FlowCash after capex | -$19M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | +91.5% |
BDRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BDRX and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $1M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | -$10M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.02x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BDRX and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BDRX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BDRX delivers a -121.4% return on equity — every $100 of shareholder capital generates $-121 in annual profit, vs $-130 for DBVT. BDRX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), BDRX scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -121.4% | -130.2% |
| ROA (TTM)Return on assets | -78.4% | -89.0% |
| ROICReturn on invested capital | -120.3% | — |
| ROCEReturn on capital employed | -75.9% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x |
| Net DebtTotal debt minus cash | -$8M | -$172M |
| Cash & Equiv.Liquid assets | $9M | $194M |
| Total DebtShort + long-term debt | $60,892 | $22M |
| Interest CoverageEBIT ÷ Interest expense | -82.66x | -189.82x |
BDRX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $0 for BDRX. Over the past 12 months, DBVT leads with a +110.4% total return vs BDRX's -93.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs BDRX's -94.0% — a key indicator of consistent wealth creation.
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -60.5% | +4.9% |
| 1-Year ReturnPast 12 months | -93.0% | +110.4% |
| 3-Year ReturnCumulative with dividends | -100.0% | +19.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -94.0% | +6.2% |
DBVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BDRX is the less volatile stock with a 1.25 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs BDRX's 5.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 1.26x |
| 52-Week HighHighest price in past year | $96.50 | $26.18 |
| 52-Week LowLowest price in past year | $2.10 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +5.0% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 60.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 922K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | BDRXBiodexa Pharmaceu… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BDRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). DBVT leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallBiodexa Pharmaceuticals Plc (BDRX)Leads 2 of 6 categories
Loading custom metrics...
BDRX vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BDRX or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BDRX or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -100. 0% for Biodexa Pharmaceuticals Plc (BDRX). Over 10 years, the gap is even starker: DBVT returned -87. 1% versus BDRX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BDRX or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Biodexa Pharmaceuticals Plc's 1. 31β — meaning BDRX is approximately 4% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Biodexa Pharmaceuticals Plc (BDRX) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — BDRX or DBVT?
On earnings-per-share growth, the picture is similar: Biodexa Pharmaceuticals Plc grew EPS 100.
0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BDRX or DBVT?
Biodexa Pharmaceuticals Plc (BDRX) is the more profitable company, earning 0.
0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDRX leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — BDRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BDRX or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BDRX or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 1%, BDRX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BDRX and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.